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Abstract
Background: Gastrointestinal stromal tumors (GISTs) represent the majority of primary non-
epithelial neoplasms of the digestive tract, most frequently expressing the KIT protein detected by
the immunohistochemical staining for the CD117 antigen. Extra-gastrointestinal stromal tumors
(EGISTs) are neoplasms with overlapping immunohistological features, occurring in the abdomen
outside the gastrointestinal tract with no connection to the gastric or intestinal wall.
Case presentation: We here report the clinical, macroscopic and immunohistological features
of an EGIST arising in the greater omentum of a 74-year-old man, with a discussion on the clinical
behavior and the prognostic factors of such lesions and a comparison with the gastrointestinal
counterpart.
Conclusion: The EGISTs in the greater omentum can grow slowly in the abdomen for a long time
without clinical appearance. In most cases a preoperative diagnosis is not possible, and the patient
undergoes a surgical operation for the generic diagnosis of "abdominal mass". During the
intervention it is important to achieve a complete removal of the mass and to examine every
possible adhesion with the gastrointestinal wall. Yamamoto's criteria based on the evaluation of the
mitotic rate and the MIB-1 labelling index seems to be useful in predicting the risk for recurrence
or metastasis. More studies are necessary to establish the prognostic factors related to localization
and size of the EGIST and to evaluate the impact of the molecular characterization as an outcome
parameter related to the molecular targeted therapy. In absence of these data, an accurate follow-
up is recommended.
Background
Stromal tumors represent the majority of primary non-
epithelial neoplasms of the digestive tract and are collec-
tively defined gastrointestinal stromal tumors (GISTs).
They histologically, immunohistochemically and geneti-
cally differ from leiomyomas, leiomyosarcomas and
schwannomas. GISTs may be defined as intra-abdominal
mesenchymal tumors most frequently expressing the KIT
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protein, having a gain-of-function mutation in the regula-
tory juxtamembrane domain of the c-kit gene or an acti-
vating mutation in another class III receptor tyrosine
kinase gene, the PDGFRA gene, which encodes the platelet
derived growth factor receptor-alpha receptor tyrosine
kinase protein [1,2]. The KIT protein can be detected by
immunohistochemical assays for the CD117 antigen.
GISTs are most commonly found in the stomach (40 to
70%), small intestine (20 to 50%) and colorectum (5 to
15%) [3-6]. Neoplasms with histology and immunohisto-
chemistry similar to GISTs may occur outside the gastroin-
testinal tract, for example in the soft tissue of the
abdominal cavity (in particular omentum and mesentery)
or in the retroperitoneum [7-9].
These tumors must be defined as extra-gastrointestinal
stromal tumors (EGISTs) since they display no connection
with the gastric or intestinal wall. While the histogenesis,
prognostic parameters and outcomes of GISTs are widely
known, pathogenesis, incidence and prognosis of EGISTs
have not yet been completely defined. A comparison
between GISTs and EGISTs is therefore of particular inter-
est in order to understand whether they have a common
cellular origin and a similar clinical behavior. We report
the results of the macroscopic and microscopic examina-
tions, including immunohistochemical studies, of an
EGIST of the greater omentum. We discuss the clinical
behavior and the prognostic factors through a review of
the literature.
Case presentation
A 74-year-old man was admitted to the Guastalla District
Hospital in October 2005 because of a large abdominal
mass. Five days before admission he was examined by his
general practitioner because of sudden lower abdominal
pain. Ultrasonography showed a nonhomogenous hypoe-
choic mass with multiple cystic components occupying
almost all the superior abdomen.
Abdominal computed tomography (CT) (Figure 1) dem-
onstrated a voluminous intraperitoneal mass, 33 × 30 ×
17 cm in size, with cystic areas, solid parts and peripheral
contrast enhancement. The bowel was dislocated without
signs of intestinal occlusion. It was not possible to state
with certainty the origin of the tumor.
Laparotomy revealed a large, slightly capsulated mass,
arising from the greater omentum and the gastro-colonic
ligament, without connection with the gastrointestinal
tract. The mass was removed "en bloc" with the greater
omentum and the gastro-colonic ligament. The tumor
seemed completely excised. In order to achieve a radical
omentectomy, the gastro-epiploic left and right vessels
were ligated at their origin, and the greater gastric curva-
ture and the transverse colon were skeletonized.
The tumor was 33 cm in maximum diameter and weighed
3500 g. On section the neoplasm consisted of whitish-
grey and relatively firm areas and cystic areas filled with
clotted blood (Figure 2).
Histologically the tumor consisted of closely packed
polygonal cells, with abundant, somewhat granular cyto-
plasm arranged in sheets or dispersed singly throughout a
finely collagenized background (Figure 3). Multinucle-
ated cells were found. The mitotic activity was < 1 mitosis/
50 high-power field (HPF). The MIB-1 labelling index was
<10%. Extensive hemorrhage, foci of mixoid degeneration
and focal necrosis were present. Immunohistochemical
studies showed strongly positive staining of tumor cells
for CD34 and CD117 (figure 4) and negative staining for
desmin, smooth muscle actin (SMA), S-100 protein.
These findings strongly supported a diagnosis of low risk
EGIST of the greater omentum. A molecular genetic anal-
ysis for KIT protein mutation was not performed for its
unavailability at our institute.
The patient had a regular hospital stay and was discharged
eight days later. An abdominal CT showed no recurrence
of disease 20 months after surgery.
CT scan showing a voluminous intraperitoneal mass 33 × 30  × 17 cm in size, occupying the most part of the abdomen,  with solid and cystic parts and with peripheral contrast  enhancement Figure 1
CT scan showing a voluminous intraperitoneal mass 
33 × 30 × 17 cm in size, occupying the most part of 
the abdomen, with solid and cystic parts and with 
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Discussion
EGISTs arise outside the gastrointestinal tract but they
share histological features with their gastrointestinal
counterpart. The clinical, pathological and prognostic fea-
tures of GISTs are widely known, while data about EGISTs
are very few: incidence, histogenesis and histological pre-
dictors of outcome are not yet defined.
EGISTs are rare tumors. Todoroki et al. [10] recently
described one case citing 28 cases previously reported in
the English-language literature. But the real incidence of
this neoplasm could be lower. Agaimy et al. [11] revalu-
ated 14 cases of EGISTs (four mesenteric, four omental,
one pararectal, one pelvic, one perivescical, one of the
mesenteric root, one involving the omentum and the
abdominal wall and one located between liver and stom-
ach). By means of a critical revaluation of the surgical
reports and clinical histories and a careful search for resid-
ual muscular tissue from the gut wall in the tumor pseu-
docapsule, it was possible to reclassify most of these cases
(11/14) either as GISTs with extramural growth or as
metastases from a GIST. This study considered crucial the
documentation by the surgeon during intervention of any
attachment or adhesion, even minimal, to the gastrointes-
tinal wall.
GISTs are currently considered as deriving from the inter-
stitial Cajal cells (ICC). These are normally part of the
autonomic nervous system of the intestine and they have
a pacemaker function in controlling motility. Most GISTs
(50–80%) arise because of a mutation in the c-kit gene.
The c-kit/CD117 receptor is expressed on ICCs, mast cells,
spermatocytes and hematopoietic cells. In the gut a tumor
staining positive for CD117 is likely to be a GIST, arising
from ICCs. The cell origin of EGISTs is controversial. Miet-
tinen and Lasota [4] claim that omental and mesenteric
Gross appearance of the neoplastic mass, consisting of solid  areas and cysts filled with clotted blood Figure 2
Gross appearance of the neoplastic mass, consisting 
of solid areas and cysts filled with clotted blood.
The tumor consists of sheets and aggregates of closely  packed polygonal cell (hematoxylin and eosin, original magni- fication 100×), with abundant somewhat granular cytoplasm,  as seen in the epitheliod type (inset, hematoxylin and eosin,  original magnification 400×) Figure 3
The tumor consists of sheets and aggregates of 
closely packed polygonal cell (hematoxylin and eosin, 
original magnification 100×), with abundant some-
what granular cytoplasm, as seen in the epitheliod 
type (inset, hematoxylin and eosin, original magnifi-
cation 400×).
The neoplastic cells are immunoreactive for CD34 (original  magnification 400×) and CD117 (inset, original magnification  200×) Figure 4
The neoplastic cells are immunoreactive for CD34 
(original magnification 400×) and CD117 (inset, origi-
nal magnification 200×).World Journal of Surgical Oncology 2008, 6:25 http://www.wjso.com/content/6/1/25
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EGISTs derive from stomach and small intestine respec-
tively, representing tumors that, for some reason, have
detached from their gastrointestinal original site during
their development. In the study of 14 EGISTs arising from
the omentum and mesentery by Li et al. [12], the multipo-
tential mesenchymal stem cells are supposed to be the ori-
gin cell of these neoplasms.
Sakurai et al. [13] found the ICC-counterpart in the omen-
tum. ICC-like cells were observed focally in the omentum
at 21 weeks of human gestation, when ICC were present
in the intermuscular space of the GI tract [14].
The prognostic factors indicating the malignant potential
of GISTs include mitotic rate, tumor size and location.
Currently, lesions that measure less than or are equal to 2
cm or which do not exceed five mitoses per 50 HPFs are
thought to have a lower malignant and metastatic poten-
tial. GISTs with a large size (> 10 cm in diameter) or with
a high mitotic count (> 10/50 HPFs) and GISTs with
diameter >5 cm and more than 5 mitotic figures/50 HPFs
are considered at high risk for recurrence [15].
In a study of more than 1000 GIST cases [5], subdivided
into five locations (esophagus, stomach, small bowel,
colorectum and peritoneum/mesentery/omentum), the
tumor site seemed an independent prognostic factor.
Esophageal tumors presented the most favorable progno-
sis, while peritoneal tumors had the lowest survival rate.
Recently, Wardelmann et al. [16] suggested to include the
molecular data together with these classical prognostic
parameters into the risk assessment of GISTs, since the
molecular characterization is not only helpful for diag-
nostic purposes in cases with low or no KIT receptor
expression but might also help to predict clinical progno-
sis as several subgroups with different risk of aggressive
clinical behavior can be identified.
Predicting the potential biological behavior of the omen-
tal EGISTs remains difficult and the literature contains
conflicting reports on this issue.
Miettinen  et al. [8] examined nine cases of omental
EGISTs and seven cases of mesenteric EGISTs. Omental
EGISTs seemed to have a more favorable behavior, typi-
cally showing low mitotic counts, whereas mesenteric
EGISTs appeared more aggressive (higher mitotic activity,
frequent malignant behavior). No tumor-related deaths
were documented during the follow-up in the nine
patients with omental EGIST.
Reith et al. [17] have examined the clinico-pathological
and immunohistochemical features of 48 EGISTs arising
within the abdominal cavity (40 cases) and the retroperi-
toneum (remaining 8 cases). The tumors ranged in size
from 2.1 to 32 cm with a median size of 12 cm and
expressed CD117 (c-kit receptor) (100%), CD34 (50%),
neuron-specific enolase (44%), SMA (26%), desmin
(4%), and S-100 protein (4%). High cellularity, mitotic
activity (>2 mitoses/50 HPF) and the presence of necrosis
were significantly associated with an adverse outcome in
univariate analyses, whereas nuclear atypia, growth pat-
tern (spindled, epithelioid, or mixed) and size were not.
The authors justified the finding of no association
between tumor size and outcome of EGIST by the fact that
the majority of EGISTs were large (>10 cm) when first
detected. On the basis of the histological appearance and
immunophenotypical profile the EGISTs seem to resem-
ble stromal tumors originated from the small intestine
rather than from the stomach.
Yamamoto et al. [7] examined the clinico-pathological
features, prognostic factors, and c-kit and PDGFRA muta-
tions in 39 cases of EGISTs including three omental
tumors. These authors have defined three categories on
the basis of a combination of the mitotic rate and MIB-1
labelling index: the high-risk group (>or=5/50 HPF with
>or=10% Ki-67), the intermediate-risk group (>or=5/50
HPF with <10% Ki-67, or, <5/50 HPF with >or=10% Ki-
67), and the low-risk group (<5/50 HPF with <10% Ki-
67). The authors claim that the shortness of the follow-up
period in the series by Reith et al. [17] (median: 24
months) may lead to a bias of their data. Moreover they
pointed out that EGISTs were often large size due to their
anatomic site, having enough space to grow and present-
ing clinical symptoms only after a long time. Therefore a
grading system defined by a combination of mitotic rate
and tumor size, which is commonly used in GISTs, may
not be applicable in EGISTs. On the contrary, the molecu-
lar characterization of GISTs as a prognostic factor [16]
can be expected to become in the next future a common
prognostic parameter for such lesions, independently
from the site of origin.
Surgery remains the standard treatment for non-meta-
static EGIST in the greater omentum [18].
In our case the resection of tumor was complete and the
neoplasm was considered at low risk for recurrence or
metastasis according to Yamamoto's criteria. The accurate
radiological follow-up (abdominal CT) has been consid-
ered the approach of choice in the control of the disease.
Conclusion
The EGISTs in the greater omentum can grow slowly in the
abdomen for a long time without clinical appearance and
they are often referred to the surgeon when they have
reached a large size. In most cases a preoperative diagnosis
is not possible, and the patient undergoes a surgical oper-Publish with BioMed Central    and   every 
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ation for the generic diagnosis of "abdominal mass", that
usually puts in apprehension both the patient and the sur-
geon. During the intervention it is important to achieve a
complete removal of the mass, when possible "en bloc"
with contiguous tissues and regional lymph nodes, even if
prognostic value of lymphatic involvement of these
tumors is still unclear. It is also crucial to examine every
possible adhesion with the gastrointestinal wall, marking
them for the pathologist. A histological diagnosis of
EGIST is often unexpected. Yamamoto's criteria seem to
be useful in predicting the risk for recurrence or metasta-
sis. More studies are necessary to establish the prognostic
factors related to localization and size of the EGIST and to
evaluate the impact of the molecular characterization as
an outcome parameter related to the molecular targeted
therapy. In absence of these data, an accurate follow-up is
recommended.
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